Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is common among older persons and is associated with an increased risk of hematologic cancer. We previously found preliminary evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature of this association was unclear. METHODS: We used whole-exome sequencing to detect the presence of CHIP in peripheral-blood cells and associated such presence with coronary heart disease using samples from four case-control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls. To assess causality, we perturbed the function of Tet2, the second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice. RESULTS: In nested case-control analyses from two prospective cohorts, carriers of CHIP had a risk of coronary heart disease that was 1.9 times as great as in noncarriers (95% confidence interval [CI], 1.4 to 2.7). In two retrospective case-control cohorts for the evaluation of early-onset myocardial infarction, participants with CHIP had a risk of myocardial infarction that was 4.0 times as great as in noncarriers (95% CI, 2.4 to 6.7). Mutations in DNMT3A, TET2, ASXL1, and JAK2 were each individually associated with coronary heart disease. CHIP carriers with these mutations also had increased coronary-artery calcification, a marker of coronary atherosclerosis burden. Hypercholesterolemia-prone mice that were engrafted with bone marrow obtained from homozygous or heterozygous Tet2 knockout mice had larger atherosclerotic lesions in the aortic root and aorta than did mice that had received control bone marrow. Analyses of macrophages from Tet2 knockout mice showed elevated expression of several chemokine and cytokine genes that contribute to atherosclerosis. CONCLUSIONS: The presence of CHIP in peripheral-blood cells was associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“That subjects with clonal hematopoiesis are more susceptible to develop nonhematological, most notably cardiovascular, disease”
From Aging of hematopoietic stem cells (2018) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are supported by recent findings demonstrating a causal link between mutations in HSPCs in the context of clonal hematopoiesis with indeterminate origin and altered transcriptional output of macrophages, which affect the vascular wall and contributes to atherosclerosis.83,84”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [83]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As CHIP-associated mutations are known to alter the development and function of myeloid cells”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tet2 and Ppm1d mutant murine models have demonstrated an increased inflammatory signature in mutant macrophages, with heightened inflammatory cytokine production upon pro-inflammatory stimulation in vitro [31,32,69,70].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated IL-8 and IL-1β levels have been reported in patients with TET2 CH in the Pakistan Risk of Myocardial Infarction Study (PROMIS) [20,32]”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [32]
Experimental — accuracy not yet measured
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Self-citationClonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Self-citationMacrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Self-citationAge-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice
Fuster, J. J., MacLauchlan, S., Zuriaga, M. A., Polackal, M. N., Ostriker, A. C., Chakraborty, R., Wu, C.-L., Sano, S., Muralidharan, S., Rius, C., et al. (2017) · Science · doi:10.1126/science.aag1381 · Cited by 1,536
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Ishibashi, S., Brown, M. S., Goldstein, J. L., Gerard, R. D., Hammer, R. E., & Herz, J. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116663 · Cited by 1,354
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Cited by
Items 201–300 of 1,015
Davis, F. M., & Gallagher, K. A. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.312135 · Cited by 167
Addressing dyslipidemic risk beyond LDL-cholesterol
Tall, A. R., Thomas, D. G., Gonzalez-Cabodevilla, A. G., & Goldberg, I. J. (2022) · Journal of Clinical Investigation · doi:10.1172/jci148559 · Cited by 150
Chromosomal alterations among age-related haematopoietic clones in Japan
Terao, C., Suzuki, A., Momozawa, Y., Akiyama, M., Ishigaki, K., Yamamoto, K., Matsuda, K., Murakami, Y., McCarroll, S. A., Kubo, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2426-2 · Cited by 154
Premature Menopause, Clonal Hematopoiesis, and Coronary Artery Disease in Postmenopausal Women
Honigberg, M. C., Zekavat, S. M., Niroula, A., Griffin, G. K., Bick, A. G., Pirruccello, J. P., Nakao, T., Whitsel, E. A., Farland, L. V., Laurie, C., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051775 · Cited by 147
Self-citationThe Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk
Nayor, M. G., Brown, K., & Vasan, R. S. (2021) · Circulation Research · doi:10.1161/circresaha.120.315890 · Cited by 160
Hematopoietic aging promotes cancer by fueling IL-1⍺–driven emergency myelopoiesis
Park, M. D., Bérichel, J. L., Hamon, P., Wilk, C. M., Belabed, M., Yatim, N., Saffon, A., Boumelha, J., Falcomatà, C., Tepper, A., et al. (2024) · Science · doi:10.1126/science.adn0327 · Cited by 170
Targeting IL-1β in the Treatment of Atherosclerosis
Mai, W., & Liao, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589654 · Cited by 154
“Moreover, the increased susceptibility of atherosclerosis associated with the presence of clonal hematopoiesis in peripheral-blood cells was regulated at least in part by the NLRP3/IL-1b pathway (19, 20).”
BackgroundAbplanalp, W. T., Mas-Peiro, S., Cremer, S., John, D., Dimmeler, S., & Zeiher, A. M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.2468 · Cited by 141
Buscarlet, M., Provost, S., Zada, Y. F., Bourgoin, V., Mollica, L., Dubé, M.-P., & Busque, L. (2018) · Blood · doi:10.1182/blood-2018-01-829937 · Cited by 146
Common Pathophysiology in Cancer, Atrial Fibrillation, Atherosclerosis, and Thrombosis
Leiva, O., AbdelHameid, D., Connors, J. M., Cannon, C. P., & Bhatt, D. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.08.011 · Cited by 155
“These age-related mutations found in genes such as DNMT3A, TET2, JAK2, and ASXL1, although they are also found in myeloid neoplasms including myelodysplastic syndromes, acute myeloid leukemia, and myeloproliferative neoplasms, in CHIP, they do not cause alterations in peripheral blood counts (83).”
BackgroundInfluentialNovel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145
Self-citationMulti-Modality Imaging in the Assessment of Cardiovascular Toxicity in the Cancer Patient
Plana, J. C., Thavendiranathan, P., Bucciarelli‐Ducci, C., & Lancellotti, P. (2018) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.06.003 · Cited by 161
“The area of vascular risk in cancer survivors, however, has gained significant attention with the description of clonal hematopoiesis (CH) as a risk factor for atherosclerotic vascular disease (17).”
BackgroundChallenges and advances in the management of inflammation in atherosclerosis
Xing, Y., & Lin, X. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.06.016 · Cited by 162
“…studies like Bioimage and the Malmo Diet and Cancer study have demonstrated that individuals with CHIP have a substantially increased risk of developing coronary heart disease (CHD) and are more likely to suffer from early-onset MI compared to those without CHIP (95 % CI: 1.4–2.7; P < 0.001) [111].”
InfluentialNtsekhe, M., & Baker, J. V. (2022) · Circulation · doi:10.1161/circulationaha.122.057443 · Cited by 150
Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
Saiki, R., Momozawa, Y., Nannya, Y., Nakagawa, M. M., Ochi, Y., Yoshizato, T., Terao, C., Kuroda, Y., Shiraishi, Y., Chiba, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01411-9 · Cited by 148
The role of ASXL1 in hematopoiesis and myeloid malignancies
Asada, S., Fujino, T., Goyama, S., & Kitamura, T. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03084-7 · Cited by 152
Clonal hematopoiesis is associated with risk of severe Covid-19
Bolton, K. L., Koh, Y., Foote, M. B., Im, H., Jee, J., Sun, C. H., Safonov, A., Ptashkin, R., Moon, J. H., Lee, J. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26138-6 · Cited by 143
Self-citationInflammasomes, neutrophil extracellular traps, and cholesterol
Tall, A. R., & Westerterp, M. (2019) · Journal of Lipid Research · doi:10.1194/jlr.s091280 · Cited by 147
“disease, especially in the elderly (57, 58).”
BackgroundNam, A. S., Dusaj, N., Izzo, F., Murali, R., Myers, R. M., Mouhieddine, T. H., Sotelo, J., Benbarche, S., Waarts, M., Gaiti, F., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01179-9 · Cited by 140
Molecular Mechanisms of Vascular Health: Insights From Vascular Aging and Calcification
Sutton, N. R., Malhotra, R. K., Hilaire, C. S., Aïkawa, E., Blumenthal, R. S., Gackenbach, G., Goyal, P., Johnson, A. L., Nigwekar, S. U., Shanahan, C. M., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317332 · Cited by 152
Chronic Myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management
Patnaik, M. M., & Tefferi, A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25684 · Cited by 145
“Both ARCH and CHIP (clonal hematopoiesis of indeterminate potential) commonly results from mutations in epigenetic regulator genes; DNMT3A, TET2 and ASXL1, and are associated with an increased incidence of hematological malignancies and all-cause mortality (largely due to cardiovascular and cerebrovascular disease).(8…”
BackgroundMakover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 159
Pathophysiology of Acute Myeloid Leukemia
Wachter, F., & Pikman, Y. (2024) · Acta Haematologica · doi:10.1159/000536152 · Cited by 158
Zhang, C. R. C., Nix, D., Gregory, M., Ciorba, M. A., Ostrander, E. L., Newberry, R. D., Spencer, D. H., & Challen, G. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.11.008 · Cited by 137
“inflammatory response in myeloid cells [11], and TET2-mutant CHIP is associated with overproduction of IL6 which promotes mutant HSC expansion [12] and accelerates atherosclerosis [13].”
BackgroundGirelli, D., Marchi, G., & Camaschella, C. (2018) · HemaSphere · doi:10.1097/hs9.0000000000000040 · Cited by 161
Granulopoiesis and Neutrophil Homeostasis: A Metabolic, Daily Balancing Act
Yvan-Charvet, L., & Ng, L. G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.004 · Cited by 129
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y.-T., Munshi, N. C., Wu, C. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004554 · Cited by 131
“particular, changes in the inflammasome, IL-1, IL-6 axis, implicated in both CHIP and CRS after CAR T-cell therapy, could influence CAR T-cell biology in individuals with CHIP.(9,10) These alterations likely have a broader impact on human disease, including in states of hyperinflammation, response to immune-targeting…”
Self-citationClonal hematopoiesis associated with epigenetic aging and clinical outcomes
Nachun, D., Lu, A. T., Bick, A. G., Natarajan, P., Weinstock, J., Szeto, M. D., Kathiresan, S., Abecasis, G., Taylor, K. D., Guo, X., et al. (2021) · Aging Cell · doi:10.1111/acel.13366 · Cited by 133
Self-citationSomatic genetic rescue in Mendelian haematopoietic diseases
Revy, P., Kannengiesser, C., & Fischer, A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-019-0139-x · Cited by 134
Trained immunity in atherosclerotic cardiovascular disease
Riksen, N. P., Bekkering, S., Mulder, W. J. M., & Netea, M. G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00894-y · Cited by 150
“Besides genetic variations 9 and clonal haematopoiesis 10,11 , both of which can affect immune cell functionality, exposure to damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns is associated with long-term, maladaptive inflammation 12,13 .”
BackgroundJakobsen, N. A., Turkalj, S., Zeng, A. G. X., Stoilova, B., Metzner, M., Rahmig, S., Nagree, M. S., Shah, S., Moore, R., Usukhbayar, B., et al. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.05.010 · Cited by 130
Losing Sense of Self and Surroundings: Hematopoietic Stem Cell Aging and Leukemic Transformation
Verovskaya, E. V., Dellorusso, P. V., & Passegué, E. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.04.006 · Cited by 127
Cardio-onco-metabolism: metabolic remodelling in cardiovascular disease and cancer
Karlstaedt, A., Moslehi, J. J., & de Boer, R. A. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00698-6 · Cited by 140
Liu, W., Östberg, N. K., Yalçınkaya, M., Dou, H., Endo‐Umeda, K., Tang, Y., Hou, X., Xiao, T., Fidler, T. P., Abramowicz, S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155724 · Cited by 139
“1% of the general European population (18), occurs at a younger age and increases coronary artery disease (12) and venous thromboembolic disease (19, 20) more prominently than the other clonal hematopoiesis variants.”
Clonal hematopoiesis: Mutation-specific adaptation to environmental change
Florez, M. A., Tran, B. T., Wathan, T. K., DeGregori, J., Pietras, E. M., & King, K. Y. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2022.05.006 · Cited by 129
Costantino, S., Libby, P., Kishore, R., Tardif, J.-C., El-Osta, A., & Paneni, F. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx568 · Cited by 130
“Genetic disruption of DNMTs (that establish or replicate DNA methylation) or MTHFR (related to methyl donor generation) in mice associate with DNA hypomethylation and subsequent increases in inflammatory mediators and formation of aortic fatty streaks.35 Atherosclerosisprone apoE / mice develop specific changes in DNA…”
BackgroundInfluentialSelf-citationMacrophages and Cardiovascular Health
Frodermann, V., & Nahrendorf, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00068.2017 · Cited by 127
Immunometabolic Crosstalk: An Ancestral Principle of Trained Immunity?
Penkov, S., Mitroulis, I., Hajishengallis, G., & Chavakis, T. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.11.002 · Cited by 125
Hellmann, M. D., Nabet, B. Y., Rizvi, H., Chaudhuri, A. A., Wells, D. K., Dunphy, M. P. S., Chabon, J. J., Liu, C. L., Hui, A. B., Arbour, K. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3418 · Cited by 125
Wang, Y., Nanda, V., DiRenzo, D. M., Ye, J., Xiao, S., Kojima, Y., Howe, K. L., Jarr, K.-U., Flores, A. M., Tsantilas, P., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006348117 · Cited by 131
“Furthermore, clonal hematopoiesis has now been definitively associated with risk for cardiovascular disease in humans (34).”
BackgroundClinical Implications of Clonal Hematopoiesis
Steensma, D. P. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.04.002 · Cited by 125
“Compelling new evidence supports the concept that inflammatory proatherogenic interactions between circulating clonally derived cells and vascular endothelium accelerate vascular disease and increase the risk of atherosclerotic plaque rupture.(6,7) In addition to aging-associated CH, CH can also occur in several other…”
BackgroundInfluentialSanders, M. A., Chew, E., Flensburg, C., Zeilemaker, A., Miller, S. E., al Hinai, A. S., Bajel, A., Luiken, B., Rijken, M., Mclennan, T., et al. (2018) · Blood · doi:10.1182/blood-2018-05-852566 · Cited by 119
Sun, L., & Babushok, D. V. (2020) · Blood · doi:10.1182/blood.2019000940 · Cited by 135
Molecular pathogenesis of the myeloproliferative neoplasms
Greenfield, G., McMullin, M. F., & Mills, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01116-z · Cited by 142
“Despite the normal blood counts, these individuals have been observed to have a significantly increased risk of cardiovascular disease [20].”
BackgroundAtherothrombosis and Oxidative Stress: Mechanisms and Management in Elderly
Violi, F., Loffredo, L., Carnevale, R., Pignatelli, P., & Pastori, D. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6963 · Cited by 118
“In contrast with this hypothesis, a recent work showed that clonal hematopoiesis of indeterminate potential (CHIP), which is a common aging-related phenomenon characterized by the presence of an expanded somatic blood-cell clone in people without hematologic disease, which may lead to an increase in circulating myeloi…”
Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway
Chen, S., Wang, Q., Yu, H., Capitano, M. L., Vemula, S., Nabinger, S. C., Gao, R., Yao, C., Kobayashi, M., Geng, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13542-2 · Cited by 123
Obesity-induced inflammation exacerbates clonal hematopoiesis
Pasupuleti, S. K., Ramdas, B., Burns, S. S., Palam, L. R., Kanumuri, R., Kumar, R., Pandhiri, T. R., Davé, U. P., Yellapu, N. K., Zhou, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163968 · Cited by 142
“Mutations in these genes can provide a competitive advantage to cells carrying them, allowing for their clonal expansion in a process known as clonal hematopoiesis (CH) (2, 4).”
BackgroundInfluentialSelf-citationHematopoietic stem cells through the ages: A lifetime of adaptation to organismal demands
Kasbekar, M., Mitchell, C. A., Proven, M. A., & Passegué, E. (2023) · Cell Stem Cell · doi:10.1016/j.stem.2023.09.013 · Cited by 132
Type-I interferons in atherosclerosis
Chen, H., Tas, S. W., & de Winther, M. P. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190459 · Cited by 129
“Alternatively, mutations in some components of the IFN regulation and signaling, such as IRF8 and JAK2, are associated with the increased risk of cardiovascular events in different populations (Jaiswal et al., 2017; Leonard et al., 2013).”
BackgroundClonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity
Cook, E. K., Luo, M., & Rauh, M. J. (2020) · Experimental Hematology · doi:10.1016/j.exphem.2020.01.011 · Cited by 121
Gullotta, G. S., Feo, D. D., Friebel, E., Semerano, A., Scotti, G. M., Bergamaschi, A., Butti, E., Brambilla, E., Genchi, A., Capotondo, A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01505-1 · Cited by 136
Potus, F., Pauciulo, M. W., Cook, E. K., Zhu, N., Hsieh, A., Welch, C. L., Shen, Y., Tian, L., Lima, P., Mewburn, J. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044320 · Cited by 133
Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss
Wang, H., Divaris, K., Pan, B., Li, X., Lim, J., Saha, G., Barovic, M., Giannakou, D., Korostoff, J. M., Bing, Y., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.003 · Cited by 135
“The epigenetic, transcriptomic, and phenotypic alterations in HSPCs and their mature progeny resulting from loss-of-function CHIP mutations affecting epigenetic modifiers 9,39,98–100 have mechanistic parallels with trained immunity.”
Self-citationThe Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies
Craver, B., El Alaoui, K., Scherber, R., & Fleischman, A. (2018) · Cancers · doi:10.3390/cancers10040104 · Cited by 116
Inflammation in atherosclerosis: Lessons and therapeutic implications
Libby, P., & Soehnlein, O. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.012 · Cited by 139
Self-citationThe role of TP53 in acute myeloid leukemia: Challenges and opportunities
Barbosa, K., Li, S., Adams, P. D., & Deshpande, A. J. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22796 · Cited by 131
“that the presence of CH is associated with an increased risk of hematological malignancies(36,67-69) and cardiovascular events.(69,70) TP53 is a crucial player in CH.”
BackgroundFigtree, G. A., Vernon, S. T., Harmer, J. A., Gray, M. P., Arnott, C. G., Bachour, E., Barsha, G., Brieger, D. B., Brown, A. D. H., Celermajer, D. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.06.045 · Cited by 128
Self-citationCobo, I., Tanaka, T. N., Chandra Mangalhara, K., Lana, A., Yeang, C., Han, C., Schlachetzki, J., Challcombe, J., Fixsen, B. R., Sakai, M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.06.022 · Cited by 113
Systemic Aging Fuels Heart Failure: Molecular Mechanisms and Therapeutic Avenues
Fang, Z., Raza, U., Song, J., Lu, J., Yao, S., Liu, X., Zhang, W., & Li, S. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14947 · Cited by 137
“…Given the common occurrence of CHIP in asymptomatic, cancer-free older individuals, its association with cardiac diseases suggests a potential causal link between somatic mutation and age-related chronic HF. 40,42 Telomeres are protective caps at chromosome ends that maintain genomic integrity.”
Platelet–Neutrophil Crosstalk in Atherothrombosis
Pircher, J., Engelmann, B., Maßberg, S., & Schulz, C. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1692983 · Cited by 125
Roles of Macrophages in Atherogenesis
Farahi, L., Sinha, S. K., & Lusis, A. J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.785220 · Cited by 122
Genetic and epigenetic determinants of AML pathogenesis
Cai, S. F., & Levine, R. L. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.001 · Cited by 137
“In addition to a higher risk of hematologic malignancy, CH patients also had an increased risk of atherosclerotic cardiovascular disease as well as all-cause mortality [15].”
BackgroundTumor-Infiltrating Clonal Hematopoiesis
Pich, O., Bernard, E., Zagorulya, M., Rowan, A., Pospori, C., Slama, R., Encabo, H. H., O’Sullivan, J., Papazoglou, D., Anastasiou, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413361 · Cited by 134
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Rautenberg, C., Germing, U., Haas, R. R., Kobbe, G., & Schroeder, T. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010228 · Cited by 123
“0% per year and thereby comparable with other pre-malignant states such as progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma [30,31].”
BackgroundVlasschaert, C., McNaughton, A. J. M., Chong, M., Cook, E. K., Hopman, W., Kestenbaum, B., Robinson-Cohen, C., Garland, J., Moran, S. M., Paré, G., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021060774 · Cited by 110
“Those who did not meet these criteria were classified as not having CHIP.”
BackgroundInfluentialClonal hematopoiesis in patients with rheumatoid arthritis
Savola, P., Lundgren, S., Keränen, M. A. I., Almusa, H., Ellonen, P., Leirisalo-Repo, M., Kelkka, T., & Mustjoki, S. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0107-2 · Cited by 112
Inflammasomes and Atherosclerosis: a Mixed Picture
Tall, A. R., & Bornfeldt, K. (2023) · Circulation Research · doi:10.1161/circresaha.123.321637 · Cited by 117
CHIP (Clonal Hematopoiesis of Indeterminate Potential)
Libby, P., & Ebert, B. L. (2018) · Circulation · doi:10.1161/circulationaha.118.034392 · Cited by 112
Self-citationBhattacharya, R., Zekavat, S. M., Uddin, M. M., Pirruccello, J., Niroula, A., Gibson, C., Griffin, G. K., Libby, P., Ebert, B. L., Bick, A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.1678 · Cited by 109
Self-citationAberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis
Weinstock, J. S., Gopakumar, J., Burugula, B. B., Uddin, M. M., Jahn, N., Belk, J. A., Bouzid, H., Daniel, B., Miao, Z., Ly, N., et al. (2023) · Nature · doi:10.1038/s41586-023-05806-1 · Cited by 118
Self-citationSNIP1 Recruits TET2 to Regulate c-MYC Target Genes and Cellular DNA Damage Response
Chen, L., Lin, H.-P., Zhou, W.-J., He, C.-X., Zhang, Z.-Y., Cheng, Z., Song, J., Liu, P., Chen, X.-Y., Xia, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.028 · Cited by 115
“, 2015), cardiac protection (Fuster et al., 2017; Jaiswal et al., 2017), and tumor suppression (Li et al.”
CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors
Reed, S. C., Croessmann, S., & Park, B. H. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2598 · Cited by 118
Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA
Semenkovich, N. P., Szymanski, J. J., Earland, N. J., Chauhan, P. S., Pellini, B., & Chaudhuri, A. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006284 · Cited by 124
Groarke, E. M., & Young, N. S. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.03.001 · Cited by 119
Luquette, L. J., Miller, M. B., Zhou, Z., Bohrson, C. L., Zhao, Y., Jin, H., Gulhan, D., Ganz, J., Bizzotto, S., Kirkham, S., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01180-2 · Cited by 108
“6 using n=73 of the 75 MDA-amplified PFC neurons from subjects analyzed in this study (the two excluded neurons are 5087pfc-Rp3C5, an extreme outlier, and 4638-MDA-14); (3) rerun of LiRA on n=74 MDA-amplified neurons in (2) using the same input provided to SCAN2; (4) SCAN2 on n=74 MDA-amplified neurons; (5) LiRA on n=…”
MethodFujino, T., Goyama, S., Sugiura, Y., Inoue, D., Asada, S., Yamasaki, S., Matsumoto, A., Yamaguchi, K., Isobe, Y., Tsuchiya, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22053-y · Cited by 103
Clonal hematopoiesis, somatic mosaicism, and age-associated disease
Evans, M. A., & Walsh, K. X. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2022 · Cited by 116
HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
Dharan, N. J., Yeh, P., Bloch, M., Yeung, M. M., Baker, D., Guinto, J., Roth, N., Ftouni, S., Ognenovska, K., Smith, D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01357-y · Cited by 108
Handy, C. E., Quispe, R., Pintó, X., Blaha, M. J., Blumenthal, R. S., Michos, E. D., Lima, J. A. C., Güallar, E., Ryu, S., Cho, J., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035516 · Cited by 112
Huang, K. K., Ma, H., Chong, R. H. H., Uchihara, T., Lian, B. S. X., Zhu, F., Sheng, T., Srivastava, S., Tay, S. T., Sundar, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.004 · Cited by 121
Vascular damage in systemic lupus erythematosus
Ambler, W. G., & Kaplan, M. J. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00797-8 · Cited by 116
“CHIP is an age-related phenomenon in which somatic mutations in myeloid stem cells result in clonal expansion with subsequent increased rates of atherosclerosis, likely mediated by increased inflammatory properties of myeloid cells 50,51 .”
Hasselbalch, H. C., & Holmström, M. O. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0700-2 · Cited by 112
Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing
Arindrarto, W., Borràs, D., de Groen, R. A. L., van den Berg, R. R., Locher, I. J., van Diessen, S. A. M. E., van der Holst, R., van der Meijden, E. D., Honders, M. W., de Leeuw, R. H., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0762-8 · Cited by 106
Calcagno, D. M., Ng, R. P., Toomu, A., Zhang, C., Huang, K., Aguirre, A. D., Weissleder, R., Daniels, L. B., Fu, Z., & King, K. R. (2020) · Science Immunology · doi:10.1126/sciimmunol.aaz1974 · Cited by 101
“Last, identification of height ened spontaneous type I IFN activation in the bone marrow of Tet2deficient mice suggests IFNs may play an unappreciated role in mediating inflammation in human clonal hematopoiesis (44, 63).”
BackgroundInflammatory Signaling Pathways in Preleukemic and Leukemic Stem Cells
Hemmati, S., Haque, T., & Gritsman, K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00265 · Cited by 101
“recently showed that loss of Tet2 in hematopoietic cells could promote atherosclerosis in the LDL-receptor knockout mouse model due to activation of macrophages (13).”
BackgroundMedical Therapy for Long-Term Prevention of Atherothrombosis Following an Acute Coronary Syndrome
Gallone, G., Baldetti, L., Pagnesi, M., Latib, A., Colombo, A., Libby, P., & Giannini, F. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.09.052 · Cited by 116
Self-citationMechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease
Narayan, V., Thompson, E. W., Demissei, B., Ho, J. E., Januzzi, J. L., & Ky, B. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.067 · Cited by 103
Bill, M., Mrózek, K., Kohlschmidt, J., Eisfeld, A., Walker, C. J., Nicolet, D., Papaioannou, D., Blachly, J. S., Orwick, S. J., Carroll, A. J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014732117 · Cited by 109
“Higher VAFs were found for mutations in such genes as ZRSR2, PLCG2, GATA2, TET2, ASXL1, and DNMT3A, the last three of which are known to be recurrently mutated in age-associated clonal hematopoiesis of indeterminate potential (26, 27).”
BackgroundClonal hematopoiesis in cardiovascular disease and therapeutic implications
Tall, A. R., & Fuster, J. J. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00015-3 · Cited by 105
Hasselbalch, H. C., Elvers, M., & Schafer, A. I. (2021) · Blood · doi:10.1182/blood.2020008109 · Cited by 117
Clonal hematopoiesis and associated diseases: A review of recent findings
Asada, S., & Kitamura, T. (2021) · Cancer Science · doi:10.1111/cas.15094 · Cited by 111
ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications
Valent, P. (2018) · Pathobiology · doi:10.1159/000489042 · Cited by 119
CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice
DeZern, A. E., Malcovati, L., & Ebert, B. L. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_239083 · Cited by 98
Self-citationHecker, J. S., Hartmann, L., Rivière, J., Buck, M. C., van der Garde, M., Rothenberg-Thurley, M., Fischer, L., Winter, S., Ksienzyk, B., Ziemann, F., et al. (2021) · Blood · doi:10.1182/blood.2020010163 · Cited by 105
“CH carriers also have higher risks of atherosclerotic cardiovascular disease (CVD), death from coronary heart disease, and all-cause mortality 3,9 .”
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management
Patnaik, M. M., & Tefferi, A. (2022) · American Journal of Hematology · doi:10.1002/ajh.26455 · Cited by 113
“ARCH or clonal hematopoiesis of indeterminate potential (CHIP) commonly results from mutations in epigenetic regulator genes; DNMT3A, TET2, and ASXL1 and is associated with an increased incidence of hematological malignancies and all-cause mortality (largely due to cardiovascular disease).(83,84) It is well known that…”
BackgroundYalçınkaya, M., Liu, W., Thomas, L.-A., Olszewska, M., Xiao, T., Abramowicz, S., Papapetrou, E. P., Westerterp, M., Wang, N., Tabas, I. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.065344 · Cited by 111
“7 However, there are no guidelines or practical approaches to address screening for CH, for example, in the elderly with multiple risk factors.”
BackgroundChronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management
Patnaik, M. M., & Tefferi, A. (2024) · American Journal of Hematology · doi:10.1002/ajh.27271 · Cited by 118
“90,91 It is well known that CMML is associated with aging, with most patients (>70”
BackgroundInnate Immune Signaling in Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases
Cai, J., Xu, M. M., Zhang, X., & Li, H. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-013003 · Cited by 106
Uddin, M. M., Nguyen, N. Q., Yu, B., Brody, J. A., Pampana, A., Nakao, T., Fornage, M., Bressler, J., Sotoodehnia, N., Weinstock, J. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33093-3 · Cited by 106
Self-citation
Metadata
- Authors
- Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., Baber, U., Mehran, R., Fuster, V., Danesh, J., Frossard, P., Saleheen, D., Melander, O., Sukhova, G. K., Neuberg, D., Libby, P., Kathiresan, S., & Ebert, B. L.
- Affiliations
- Brigham and Women's Hospital (US)
- Broad Institute (US)
- ORCID
- Jaiswal, Siddhartha
- Natarajan, Pradeep
- Silver, Alexander J.
- Gibson, Christopher J.
- Bick, Alexander G.
- McConkey, Marie
- Gupta, Namrata
- Gabriel, Stacey
- Ardissino, Diego
- Baber, Usman
- Mehran, Roxana
- Danesh, John
- Saleheen, Danish
- Melander, Olle
- Sukhova, Galina K.
- Neuberg, Donna
- Libby, Peter
- Kathiresan, Sekar
- Ebert, Benjamin L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-13
- Volume
- 377
- Issue
- 2
- Pages
- 111-121
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6717509
- OpenAlex
- W2628145035
- Cited by
- 2,683
- References
- 37
- Citations by year
- 2026: 303 · 2025: 322 · 2024: 347 · 2023: 338 · 2022: 371 · 2021: 303 · 2020: 263 · 2019: 215 · 2018: 169 · 2017: 44
- FWCI
- 143.91
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Apollo
- Funders
- Wellcome Trust
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- Novo Nordisk Fonden (NNF14OC0009819, NNF13OC0005339)
- Medical Research Council (MR/L003120/1)
- National Heart, Lung, and Blood Institute (R01HL082945, R01HL080472, RC2HL101834, T32HL116324)
- National Human Genome Research Institute (U54HG003067)
- Fogarty International Center (RC1TW008485)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- clonal hematopoiesis of indeterminate potential, atherosclerotic cardiovascular disease, coronary artery disease, myocardial infarction, coronary artery calcification, TET2 mutation, DNMT3A, ASXL1, JAK2, somatic mutations, atherosclerosis, cytokines and chemokines, macrophages, bone marrow transplantation
- MeSH terms
- Animals, Coronary Disease, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mutation, Risk, Case-Control Studies, Sequence Analysis, DNA, Mice, Knockout, Genetic Predisposition to Disease, Atherosclerosis, Mice, Exome, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.